Clinical Trial Update: Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients [Phase 1]

View source ↗

Summary

Phase 1 dose-titration and open-label extension study of SRP-4045 in advanced Duchenne Muscular Dystrophy completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• SRP-4045

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Duchenne Muscular Dystrophy | Phase 1 | Status: COMPLETED | Results posted: 2021-05-17